报价延迟最少15分钟:2026/04/25 04:12 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
41.17 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
23.03/20.80
|
|
企业价值
289.79B
|
| 资产负债 |
|
每股账面净值
6.90
|
| 现金流量 |
|
现金流量率
0.11
|
| 损益表 |
|
收益
309.06B
|
|
每股收益
6.85
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders. |
